Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer

被引：78

作者：

Mano, Y ^{[1
]}

Kikuchi, Y ^{[1
]}

Yamamoto, K ^{[1
]}

Kita, T ^{[1
]}

Hirata, J ^{[1
]}

Tode, T ^{[1
]}

Ishii, K ^{[1
]}

Nagata, I ^{[1
]}

机构：

[1] Natl Def Med Coll, Dept Obstet & Gynecol, Tokorozawa, Saitama 3598513, Japan

来源：

EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷 / 08期

关键词：

bcl-2; cisplatin; ovarian cancer; p53; MDM-2; cisplatin resistance; apoptosis;

D O I：

10.1016/S0959-8049(99)00124-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This retrospective study of ovarian cancer aimed to elucidate whether expression of apoptosis-related proteins, bcl-2, p53 or MDM-2, is associated with resistance to chemotherapy, especially cisplatin (CDDP) based chemotherapy. Expression of bcl-2, p53 and MDM-2, was assessed by immunohistochemical staining of tumour tissues collected at initial surgery prior to treatment with CDDP-based chemotherapy. Among 66 patients with advanced ovarian cancer with measurable tumour following surgery and evaluable for response to chemotherapy, 42, 45 and 56% were positive for bcl-2, p53 and MDM-2, respectively. Significantly fewer tumours of patients who had a complete response to chemotherapy (CR) showed positivity for bcl-2 (2/20) than for p53 (6/20) and MDM-2 (8/20, P < 0.001). There was an inverse correlation between bcl-2 staining and initial response to chemotherapy, especially in serous and endometrial adenocarcinomas. In patients with stage III-IV, serous or endometrioid adenocarcinomas, significantly poorer survival was seen for those with bcl-2 positive tumours than those with negative bcl-2 staining (P= 0.0064). p53 and MDM-2 were not correlated with initial response to chemotherapy. Multivariate analysis revealed that bcl-2, residual tumour size and histology were significant independent prognostic factors. These results suggest that bcl-2 can be a possible predictor of response to chemotherapy and prognosis in patients with advanced ovarian carcinoma. (C) 1999 Elsevier Science Ltd. All rights reserved.

引用

页码：1214 / 1219

页数：6

共 25 条

[11]

MAESTRO R, 1992, ONCOGENE, V7, P1159

[12] THE PROGNOSTIC-SIGNIFICANCE OF RESIDUAL DISEASE, FIGO SUBSTAGE, TUMOR HISTOLOGY, AND GRADE IN PATIENTS WITH FIGO STAGE-III OVARIAN-CANCER [J].

MAKAR, AP ;

BAEKELANDT, M ;

TROPE, CG ;

KRISTENSEN, GB .

GYNECOLOGIC ONCOLOGY, 1995, 56 (02) :175-180

[13]

Manne U, 1997, INT J CANCER, V74, P346, DOI 10.1002/(SICI)1097-0215(19970620)74:3<346::AID-IJC19>3.0.CO

[14]

2-9

[15] Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer [J].

Marx, D ;

Meden, H ;

Ziemek, T ;

Lenthe, T ;

Kuhn, W ;

Schauer, A .

EUROPEAN JOURNAL OF CANCER, 1998, 34 (06) :845-850

[16]

MIYASHITA T, 1993, BLOOD, V81, P151

[17] THE MDM-2 ONCOGENE PRODUCT FORMS A COMPLEX WITH THE P53 PROTEIN AND INHIBITS P53-MEDIATED TRANSACTIVATION [J].

MOMAND, J ;

ZAMBETTI, GP ;

OLSON, DC ;

GEORGE, D ;

LEVINE, AJ .

CELL, 1992, 69 (07) :1237-1245

[18] THE MDM-2 GENE IS INDUCED IN RESPONSE TO UV-LIGHT IN A P53-DEPENDENT MANNER [J].

PERRY, ME ;

PIETTE, J ;

ZAWADZKI, JA ;

HARVEY, D ;

LEVINE, AJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (24) :11623-11627

[19]

PIETENPOL JA, 1994, CANCER RES, V54, P3714

[20]

Sakuragi N, 1998, INT J CANCER, V79, P153, DOI 10.1002/(SICI)1097-0215(19980417)79:2<153::AID-IJC10>3.0.CO

← 1 2 3 →